Sun D-Q, Jin Y, Wang T-Y, Zheng KI, Rios RS, Zhang H-Y, et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433.
D’Agati VD, Chagnac A, de Vries APJ, Levi M, Porrini E, Herman-Edelstein M, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12(8):453–71.
Gregg EW, Shaw JE. Global health effects of overweight and obesity. N Engl J Med. 2017;377(1):80–1.
Wei L, Li Y, Yu Y, Xu M, Chen H, Li L, et al. Obesity-related Glomerulopathy: from mechanism to therapeutic target. Diabetes Metab Syndr Obes. 2021;14:4371–80.
Wang Z, Huang W, Li H, Tang L, Sun H, Liu Q, et al. Synergistic action of inflammation and lipid dysmetabolism on kidney damage in rats. Ren Fail. 2018;40(1):175–82.
Yang P, Xiao Y, Luo X, Zhao Y, Zhao L, Wang Y, et al. Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice. J Lipid Res. 2017;58(7):1417–27.
Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5(12):713–21.
de Vries APJ, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417–26.
Weber GJ, Foster J, Pushpakumar SB, Sen U. Altered microRNA regulation of short chain fatty acid receptors in the hypertensive kidney is normalized with hydrogen sulfide supplementation. Pharmacol Res. 2018;134:157–65.
Zaky A, Glastras SJ, Wong MYW, Pollock CA, Saad S. The role of the gut microbiome in diabetes and obesity-related kidney disease. Int J Mol Sci. 2021;22(17):9641. https://doi.org/10.3390/ijms22179641.
Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278(13):11312–9.
Navalón-Monllor V, Soriano-Romaní L, Silva M, Hazas Las, de MCL, Hernando-Quintana N, Suárez Diéguez T, et al. Microbiota dysbiosis caused by dietetic patterns as a promoter of Alzheimer’s disease through metabolic syndrome mechanisms. Food Funct. 2023;14(16):7317–34.
Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–7.
Ji C, Lu F, Wu Y, Lu Z, Mo Y, Han L, et al. Rhubarb Enema Increasing Short-Chain Fatty acids that improves the intestinal Barrier disruption in CKD may be related to the regulation of Gut Dysbiosis. Biomed Res Int. 2022;2022:1896781.
Xi X, Liu N, Wang Q, Chu Y, Yin Z, Ding Y, et al. ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma. Cell Death Dis. 2019;10(10):757.
Guo H, Song Y, Li F, Fan Y, Li Y, Zhang C, et al. ACT001 suppressing M1 polarization against inflammation via NF-κB and STAT1 signaling pathways alleviates acute lung injury in mice. Int Immunopharmacol. 2022;110:108944.
Tong L, Li J, Li Q, Wang X, Medikonda R, Zhao T, et al. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics. 2020;10(13):5943–56. https://doi.org/10.7150/thno.41498.
Cai L, Gong Q, Qi L, Xu T, Suo Q, Li X, et al. ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway. Cell Commun Signal. 2022;20(1):56.
Luo H, Liu X, Liu H, Wang Y, Xu K, Li J, et al. ACT001 Ameliorates ionizing radiation-induced lung injury by inhibiting NLRP3 inflammasome pathway. Biomed Pharmacother. 2023;163:114808.
Zhou H, Niu B, Wu X, Chu W, Zhou Y, Chen Z, et al. iTRAQ-based quantitative proteomics analysis of the effect of ACT001 on non-alcoholic steatohepatitis in mice. Sci Rep. 2023;13(1):11336.
Li X, Xiao Y, Huang Y, Song L, Li M, Ren Z. Lactobacillus gasseri RW2014 ameliorates hyperlipidemia by modulating bile acid metabolism and gut microbiota composition in rats. Nutrients. 2022;14(23):4945. https://doi.org/10.3390/nu14234945.
Fang C, Pan J, Qu N, Lei Y, Han J, Zhang J, et al. The AMPK pathway in fatty liver disease. Front Physiol. 2022;13:970292.
Chen L, Li L, Han Y, Lv B, Zou S, Yu Q. Tong-fu-li-fei decoction exerts a protective effect on intestinal barrier of sepsis in rats through upregulating ZO-1/occludin/claudin-1 expression. J Pharmacol Sci. 2020;143(2):89–96.
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–103.
Li YJ, Chen X, Kwan TK, Loh YW, Singer J, Liu Y, et al. Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A. J Am Soc Nephrol. 2020;31(6):1267–81.
Cao H, Liu J, Shen P, Cai J, Han Y, Zhu K, et al. Protective effect of Naringin on DSS-Induced Ulcerative Colitis in mice. J Agric Food Chem. 2018;66(50):13133–40.
Li Z, Song Y, Xu W, Chen J, Zhou R, Yang M, et al. Pulsatilla chinensis saponins improve SCFAs regulating GPR43-NLRP3 signaling pathway in the treatment of ulcerative colitis. J Ethnopharmacol. 2023;308:116215.
Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829.
Al Mahri S, Malik SS, Al Ibrahim M, Haji E, Dairi G, Mohammad S. Free Fatty Acid Receptors (FFARs) in adipose: physiological role and therapeutic outlook. Cells. 2022;11(4):750. https://doi.org/10.3390/cells11040750.
Zeng X, Li J, Shan W, Lai Z, Zuo Z. Gut microbiota of old mice worsens neurological outcome after brain ischemia via increased valeric acid and IL-17 in the blood. Microbiome. 2023;11(1):204.
Yoshida H, Ishii M, Akagawa M. Propionate suppresses hepatic gluconeogenesis via GPR43/AMPK signaling pathway. Arch Biochem Biophys. 2019;672:108057.
Deng M, Qu F, Chen L, Liu C, Zhang M, Ren F, et al. SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. J Endocrinol. 2020;245(3):425–37.
Juszczak F, Caron N, Mathew AV, Declèves AE. Critical role for AMPK in metabolic disease-induced chronic kidney disease. Int J Mol Sci. 2020;21(21):7994. https://doi.org/10.3390/ijms21217994.
Declèves A-E, Zolkipli Z, Satriano J, Wang L, Nakayama T, Rogac M, et al. Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int. 2014;85(3):611–23.
Kang C, Wang B, Kaliannan K, Wang X, Lang H, Hui S, et al. Gut microbiota mediates the protective effects of dietary capsaicin against chronic low-grade inflammation and associated obesity induced by high-fat diet. mBio. 2017;8(3):e00470–17. https://doi.org/10.1128/mBio.00470-17. Erratum in: MBio. 2017;8(4).
Guo Y-P, Jiang H-K, Jiang H, Tian H-Y, Li L. Lipoxin A4 may attenuate the progression of obesity-related glomerulopathy by inhibiting NF-κB and ERK/p38 MAPK-dependent inflammation. Life Sci. 2018;198:112–8.
Ding X, Jian T, Li J, Lv H, Tong B, Li J, et al. Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NFκB Signaling Pathway and Restores Gut Microbiota in High-Fat-Diet-Fed Mice. Oxid Med Cell Longev. 2020;2020:9734560.
Dugan LL, You Y-H, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves A-E, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 2013;123(11):4888–99.
Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003;73(2):209–12.
Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi B-S, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22(2):317–26.
Prem PN, Chellappan DR, Kurian GA. High-fat diet-induced mitochondrial dysfunction is associated with loss of protection from ischemic preconditioning in renal ischemia reperfusion. Pflugers Arch. 2023;475(5):637–53.
Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol. 2017;13(10):629–46.
Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013;83(6):1029–41.
Tanase DM, Gosav EM, Anton MI, Floria M, Seritean Isac PN, Hurjui LL, et al. Oxidative stress and NRF2/KEAP1/ARE pathway in Diabetic Kidney Disease (DKD): new perspectives. Biomolecules. 2022;12(9):1227. https://doi.org/10.3390/biom12091227.
Zimmermann K, Baldinger J, Mayerhofer B, Atanasov AG, Dirsch VM, Heiss EH. Activated AMPK boosts the Nrf2/HO-1 signaling axis–A role for the unfolded protein response. Free Radic Biol Med. 2015;88(Pt B):417–26.
Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.
Add Comment